Famous Wall Street Short Seller Is Taking Aim At MicroStrategy: Should You Worry?
Jim Chanos has said he is actively shorting MicroStrategy.
Chanos poked at MicroStrategy's NAV premium.
Presto Research has weighed in on whether investors should worry.
Long-time investors in MicroStrategy (NASDAQ:MSTR) have probably weathered it all, from early concerns over the risks of the firm's Bitcoin accumulation strategy to harsh mockery in bear markets and questions over whether the firm can sustain demand with the emergence of spot exchange-traded funds and copycat firms.
But even for these investors with nerves of steel forged through many fires, it is hard not to get unnerved hearing that one of the most famous short sellers in history, Jim Chanos, has taken aim at the business.
Should you worry?
Don't Miss:
— no wallets, just price speculation and free paper trading to practice different strategies.
Grow your IRA or 401(k) with Crypto – .
Chanos told CNBC in an interview on Wednesday that he was shorting MicroStrategy while longing Bitcoin.
The investor most famous for finding cracks in Enron's business and successfully shorting it ahead of its eventual collapse slammed MicroStrategy's valuation at a premium to Bitcoin as 'ridiculous' even as other firms are copying its playbook of using leverage to accumulate the digital asset.
Chanos told CNBC he was 'short the spread' because it was 'so levered to the price.'
'We're doing exactly what MicroStrategy and [executive chairman] Michael Saylor are doing,' he added. 'We're selling MicroStrategy stock and buying bitcoin and basically buying something for $1, selling it for two and a half dollars.'
Meanwhile, this trade does not mean Chanos is bullish on Bitcoin or sees value in it.
'I don't know where bitcoin is going. A hundred thousand, a million, 10,000? I don't know, I don't think anybody else knows,' he told CNBC. 'But what I do know is it's generally profitable to short $1 for two and a half dollars or $3.'
To Chanos, it is simply an arbitrage opportunity betting on MicroStrategy's premium to net asset value shrinking. The firm currently trades at 1.8 times the premium to its Bitcoin holdings, boasting a market cap of $108 billion against $59 billion worth of Bitcoin. This premium hit a high of 2.5 times the NAV in October.
Trending: New to crypto? on Coinbase.
In a Friday note, cryptocurrency research firm Presto Research said there was 'no reason for panic' among MicroStrategy investors over Chanos' trade.
'MSTR's periodic BTC accumulation resembles a growing balance sheet fueled by recurring income. This allows investors who view BTC as an eventual store of value to assign an earnings multiple to MSTR's BTC acquisitions,' the firm said, justifying MicroStrategy's premium.
In simple terms, the argument is that if investors believe that Bitcoin will be worth more in the future, they can value MicroStrategy not just by the current price of its Bitcoin holdings but also by the expected growth of its holdings and earnings from those holdings as the price appreciates.
But Presto Research noted that this valuation model may not hold in a bear market, making Chanos' trade a complex bet on a BTC downturn.
'Whether Chanos understands Bitcoin enough to make that call remains questionable,' the firm said.
Chanos wound down his hedge fund in November 2023 as years-long losing shorts against Tesla and AOL weighed on his profitability.
'The marketplace for what I do has changed,' Chanos told The Wall Street Journal at the time.
Read Next:
A must-have for all crypto enthusiasts: .
'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones.
Image: Shutterstock
Send To MSN: 0
This article Famous Wall Street Short Seller Is Taking Aim At MicroStrategy: Should You Worry? originally appeared on Benzinga.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the best low priced pharma stocks to buy now. On July 13, Amylyx Pharmaceuticals announced new exploratory analyses from its Phase 2 PREVENT and Phase 2b clinical trials of avexitide for post-bariatric hypoglycemia/PBH at the Endocrine Society's annual meeting (ENDO 2025). Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist and has received FDA Breakthrough Therapy designation for PBH. PBH is a complication that can arise after bariatric surgery, such as Roux-en-Y gastric bypass. A medical scientist in a lab coat gazing at a microscopic view of a drug in development. There are currently no FDA-approved treatments for PBH. Avexitide works by binding to the GLP-1 receptor on pancreatic islet beta cells, blocking the effect of excessive GLP-1 and thus mitigating hypoglycemia by decreasing insulin secretion and stabilizing glucose levels. Avexitide has generally been well-tolerated with a favorable safety profile across all trials. Amylyx expects to complete recruitment for the LUCIDITY trial this year, with topline data anticipated in H1 2026. Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is a clinical-stage pharmaceutical company that discovers and develops treatment options for neurodegenerative diseases and endocrine conditions in the US. While we acknowledge the potential of AMLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
7 minutes ago
- CNBC
CNBC Exclusive: Excerpts: BlackRock Chairman & CEO Larry Fink Speaks with CNBC's Brian Sullivan on 'Money Movers' Today
WHEN: Today, Tuesday, July 15, 2025 WHERE: CNBC's "Money Movers" Following are excerpts from the unofficial transcript of a CNBC exclusive interview with BlackRock Chairman & CEO Larry Fink on CNBC's "Money Movers" (M-F, 11AM-12PM ET) today, Tuesday, July 15. Following is a link to video on All references must be sourced to CNBC. FINK ON INFRASTRUCTURE AT THE BEGINNING OF A GOLDEN AGE LARRY FINK: We believe infrastructure is just at the beginning of a golden age. And I'll get into that. We believe private credit will continue to grow and evolve. We did HBS BRIAN SULLIVAN: That's HBS. FINK: But also we believe that if you're going to be, if you believe there's going to be a melding between public and private markets, which we believe that's going to happen. FINK ON INFRASTRUCTURE INVESTMENT FINK: We believe that there's a need for trillions of dollars investing in infrastructure related to our power grids, AI, the whole digitization of an economy. We are still going to be investing in decarbonization. So all these different investments. SULLIVAN: They go together, don't they? FINK: They all go together. Plus making sure that we have adequate, you know, dispatchable energy. So all of this is all part of a plan. And we only had one target when we determined we needed to get even larger in infrastructure. And that was GIP. FINK ON PUBLIC AND PRIVATE INVESTING FINK: We're going to have to do more and more public and private investing. I do believe deficits have consequences. And I've been discussing with this administration and many other governments that we need growth to reduce the dependency of our deficits. If we don't have economic growth around 3%, our deficits, our federal deficits are going to overwhelm the economy in the future. So the only way to get out of it is growth. FINK ON PRIVATE CAPITAL FINK: I think there's enough private capital to put the put the money to work working with state and local governments, working with the hyperscalers. And we need to make sure we do this because the US has to win and lead in AI and infrastructure. It is imperative. And so, you know, we need to find these solutions and we need to rapidly find the solutions. The money is there. The opportunity is there. BlackRock is going to be integral in this process.
Yahoo
8 minutes ago
- Yahoo
Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")
NEW YORK, July 10, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company's novel secreted-Klotho (s-KL) promoter, gene and delivery system (KLTO-202, or for the treatment of ALS. The FDA grants Orphan Drug Designation to drugs and biologics that are intended for safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. The Orphan Drug Designation provides certain incentives, such as tax credits, toward the cost of human clinical trials and a waiver for the payment of the GDUFA User Fee for market applications. Additionally, Orphan Drug Designation of the product provides the developers seven years of US market exclusivity and independent from the Company's intellectual property protection. "Receiving the Orphan Drug Designation for for the early treatment of ALS underscores the importance of bringing new treatment options to patients suffering from this rare, universally fatal disease" said Dr. Joseph Sinkule, Klotho's Chief Executive Officer. "My cousin Karen died from this horrific disease. We aim to deliver the first gene replacement therapy addressing the neurologic insult resulting in motor neuron damage and the potential neurologic protection induced by providing therapeutic blood, brain, and muscle concentrations of the s-KL protein. After the FDA's review of the data leading to the Orphan Drug Designation, we believe this ODD designation provides strong validation of our science and our approach to treat this disease" concludes Dr. Sinkule. ALS is sometimes referred to as Lou Gehrig's disease. Lou Gehrig, who played for the New York Yankees for 17 years in the 1920s and 1930s, stunned players and fans by retiring from baseball at the age of 36 after being diagnosed with ALS. Prior to this diagnosis, Gehrig played in a record-breaking 2,130 consecutive games, was referred to as the "Iron Horse," and was considered one of the greatest baseball players of all time. Less than two years later, at the age of 37, Gehrig died of complications from ALS. ALS is also referred to as Motor Neuron Disease in the UK and elsewhere. ALS is considered a rare disease and affects fewer than 200,000 people in the US, with around 5,000 new cases diagnosed each year. Klotho Neurosciences will have completed "proof of concept" studies in two animal models of human ALS and the Company is currently initiating manufacturing of the ALS-targeted product candidate, followed by meetings with the U.S. FDA and EMA in Europe to concur with the development path going forward. KLTO-202, the company's lead product candidate targeting motor neuron diseases and muscular dystrophies, is composed of a muscle-specific promoter called "desmin," driving the expression of the s-KL gene transcript and s-KL protein, with targeted delivery of the gene therapy to the neuromuscular junction - the interface between the spinal cord and the muscles. At this time, KLTO-202 is not approved for human use by any regulatory authority. About Klotho Neurosciences, Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The Company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization. For more information, please visit the company's website at Investor Contact and Corporate Communications: - Jeffrey LeBlanc, CFOir@ Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC's website, All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. View original content to download multimedia: SOURCE Klotho Neurosciences, Inc.
